Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Not listed No phase listed Observational Accepts healthy volunteers

Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD

NCT05663671
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Colitis, Indeterminate Colitis
Interventions
Diagnostic Test
Diagnostic Test
Lead sponsor
Meharry Medical College
Other
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Colitis, Ulcerative
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of Rosiglitazone for Ulcerative Colitis

NCT00065065
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 9 more
Completed Phase 4 Interventional Results available

C. Difficile and Ursodiol

NCT02748616
Conditions
Diarrhea
Interventions
Ursodiol
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Crohn's Disease, Ulcerative Colitis (UC), Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
Interventions
Empowered Relief, Living Better with Chronic Pain
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 1 mg per kg, Golimumab 2 mg per kg, Golimumab 4 mg per kg
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Orange, California • Roseville, California • Littleton, Colorado + 33 more
Conditions
Graft Vs Host Disease, Colitis, Crohn Disease
Interventions
MSOT Device, Temperature Measurement
Device · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Ulcerative Colitis
Interventions
Etrozulimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Completed Phase 3 Interventional Accepts healthy volunteers Results available

ENhanced Recovery in CHildren Undergoing Surgery

NCT04060303
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Perioperative surgical care
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
10 Years to 18 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
Interventions
Group 1: Placebo, Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 81 more
Conditions
Ulcerative Colitis
Interventions
BT-11 (440 mg), BT-11 (880 mg), Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Ventura, California • Walnut Creek, California + 6 more
Conditions
Inflammatory Bowel Disease
Interventions
2 Family-based problem solving phone sessions, 4 Family-based problem solving phone intervention sessions, Wait list comparison group
Behavioral
Lead sponsor
Rosalind Franklin University of Medicine and Science
Other
Eligibility
11 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Ulcerative Colitis
Interventions
tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
62
States / cities
Tucson, Arizona • Oceanside, California • San Diego, California + 33 more
Recruiting No phase listed Observational Accepts healthy volunteers

Familial Inflammatory Bowel Disease Early Risk

NCT07791862
Conditions
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn Disease (CD), Ulcerative Colitis (UC)
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Years to 55 Years
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2036
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Colitis, Ulcerative
Interventions
VTX002, Placebo
Drug
Lead sponsor
Oppilan Pharma Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
19
States / cities
Garden Grove, California • Lancaster, California • San Diego, California + 16 more
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Dothan, Alabama • Lancaster, California • New Haven, Connecticut + 19 more
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Colitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California